| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/17425255.2017.1378342 |
| P8608 | Fatcat ID | release_cx5simgbuzb3xovowlphhgkcau |
| P698 | PubMed publication ID | 28885074 |
| P50 | author | Samaneh Soleymani | Q60594489 |
| Roja Rahimi | Q60595537 | ||
| Mohammad Abdollahi | Q37830087 | ||
| Roodabeh Bahramsoltani | Q38544363 | ||
| P2860 | cites work | Lack of pharmacokinetic interaction between St. John's wort and prednisone | Q46958985 |
| The effect of induction of CYP3A4 by St John's wort on ambrisentan plasma pharmacokinetics in volunteers of known CYP2C19 genotype | Q47803945 | ||
| The disposition of prasugrel, a novel thienopyridine, in humans. | Q50700156 | ||
| Interaction between a commercially available St. John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia. | Q51465582 | ||
| Wound-healing activity of St. John's Wort (Hypericum perforatum L.) on chicken embryonic fibroblasts. | Q53584005 | ||
| Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. | Q54593894 | ||
| Indinavir concentrations and St John's wort. | Q55033637 | ||
| Overview of P-glycoprotein inhibitors: a rational outlook | Q56029440 | ||
| Influence of St. Johnâ s wort on the steadystate pharmacokinetics and metabolism of bosentan | Q56829810 | ||
| Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics | Q24656624 | ||
| St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor | Q24681068 | ||
| Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentan | Q26851546 | ||
| Opioid metabolism | Q28250437 | ||
| In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6 | Q28344127 | ||
| Effects of St. John's wort on irinotecan metabolism | Q33184162 | ||
| Pharmacokinetic interactions of drugs with St John's wort | Q33204911 | ||
| Effects of bupropion on simulated demand for cigarettes and the subjective effects of smoking | Q33759622 | ||
| Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation | Q34015667 | ||
| Amlodipine metabolism in human liver microsomes and roles of CYP3A4/5 in the dihydropyridine dehydrogenation | Q34389546 | ||
| Interaction between cyclosporine and Hypericum perforatum (St. John's wort) after organ transplantation | Q34421963 | ||
| Cytochrome P450 family 1 inhibitors and structure-activity relationships | Q34436975 | ||
| Warfarin and its interactions with foods, herbs and other dietary supplements | Q34566453 | ||
| Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial. | Q34573384 | ||
| Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions | Q34592877 | ||
| The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity | Q34624728 | ||
| Metabolic activation of benzodiazepines by CYP3A4. | Q34878735 | ||
| Molecular mechanisms underlying St. John's wort drug interactions | Q34902089 | ||
| Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations | Q35009679 | ||
| Intake of St John's wort improves the glucose tolerance in healthy subjects who ingest metformin compared with metformin alone | Q35023736 | ||
| The metabolism of diclofenac--enzymology and toxicology perspectives | Q35181095 | ||
| Plant-derived natural medicines for the management of depression: an overview of mechanisms of action | Q35568075 | ||
| Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals | Q35776638 | ||
| St Johns wort increases expression of P-glycoprotein: implications for drug interactions | Q35804331 | ||
| Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions | Q35806425 | ||
| Interaction of St John's wort with low‐dose oral contraceptive therapy: a randomized controlled trial | Q35825530 | ||
| Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients | Q35846658 | ||
| Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism | Q35846917 | ||
| Drug interactions with St John's wort : mechanisms and clinical implications | Q35879020 | ||
| Effects of treatment with a commercially available St John's Wort product (Movina) on cholesterol levels in patients with hypercholesterolemia treated with simvastatin | Q36048039 | ||
| Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. | Q36542670 | ||
| Pharmacogenetics of paclitaxel metabolism | Q36648319 | ||
| Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome | Q37146918 | ||
| Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke | Q44946956 | ||
| Induction of imatinib metabolism by hypericum perforatum | Q45007465 | ||
| Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19. | Q45077998 | ||
| Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction. | Q45095090 | ||
| Pharmacokinetics and metabolism of metoprolol and propranolol in the female DA and female Wistar rat: the female DA rat is not always an animal model for poor metabolizers of CYP2D6. | Q45198398 | ||
| Intensive lipid lowering with atorvastatin in patients with stable coronary disease | Q45310626 | ||
| St. John's Wort in patients non-responders to clopidogrel undergoing percutaneous coronary intervention: a single-center randomized open-label trial (St. John's Trial). | Q45710775 | ||
| Protective effects of a flavonoid-rich extract of Hypericum perforatum L. against hydrogen peroxide-induced apoptosis in PC12 cells. | Q45957428 | ||
| The inhibitory effect of Hypericum perforatum extract on morphine withdrawal syndrome in rat and comparison with clonidine. | Q46049328 | ||
| Reduced efficacy of rosuvastatin by St. John's Wort | Q46137737 | ||
| Does St. John's wort interfere with the antiandrogenic effect of oral contraceptive pills? | Q46144502 | ||
| Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine | Q46175757 | ||
| The effect of St. John's wort on the pharmacokinetics, metabolism and biliary excretion of finasteride and its metabolites in healthy men. | Q46203034 | ||
| Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5. | Q46235505 | ||
| St John's wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive | Q46240940 | ||
| The effect of Hypericum perforatum (St. John's Wort) on experimental colitis in rat. | Q46406436 | ||
| Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding | Q46507921 | ||
| Cyclosporine and sirolimus interaction in a kidney transplant patient. | Q46554385 | ||
| Stereoselective oxidation and glucuronidation of carvedilol in human liver and intestinal microsomes | Q46562393 | ||
| Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics | Q46589222 | ||
| Time-dependent induction of midazolam-1-hydroxylation enzymes in rats treated with St. John's wort | Q46633909 | ||
| Extracts of Valeriana officinalis L. s.l. show anxiolytic and antidepressant effects but neither sedative nor myorelaxant properties | Q46832826 | ||
| Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents | Q37441245 | ||
| Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans | Q37641606 | ||
| A review of the antibacterial activity of Hypericum perforatum L. | Q37775730 | ||
| Importance of P-glycoprotein for drug-drug interactions | Q37811965 | ||
| An update on the ability of St. John's wort to affect the metabolism of other drugs | Q38011191 | ||
| Telaprevir: pharmacokinetics and drug interactions | Q38041320 | ||
| Pharmacogenetics of olanzapine metabolism | Q38127716 | ||
| The influence of herbal medicine on platelet function and coagulation: a narrative review | Q38404055 | ||
| Phytochemical constituents as future antidepressants: a comprehensive review | Q38543037 | ||
| Hypolipidemic and Antiobesity-Like Activity of Standardised Extract of Hypericum perforatum L. in Rats. | Q38760267 | ||
| Clinical Pharmacokinetics of indomethacin | Q39567269 | ||
| Hypericin phototoxicity induces different modes of cell death in melanoma and human skin cells | Q40002285 | ||
| Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes. | Q40428583 | ||
| Drug interaction between St John's Wort and quazepam. | Q42158860 | ||
| Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers | Q42224973 | ||
| Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial | Q42598774 | ||
| Effect of St John's wort on imatinib mesylate pharmacokinetics | Q42637650 | ||
| Drug interaction between St John’s wort and zolpidem in healthy subjects | Q42681226 | ||
| Bioactivation of sitaxentan in liver microsomes, hepatocytes, and expressed human P450s with characterization of the glutathione conjugate by liquid chromatography tandem mass spectrometry | Q42710944 | ||
| St John's wort greatly reduces the concentrations of oral oxycodone | Q43182631 | ||
| Effect of St. John's wort supplementation on the pharmacokinetics of bupropion in healthy male Chinese volunteers | Q43183967 | ||
| Drug interaction between St John's wort and nevirapine | Q43556089 | ||
| Metabolism of sirolimus and its derivative everolimus by cytochrome P450 3A4: insights from docking, molecular dynamics, and quantum chemical calculations | Q43624984 | ||
| The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity | Q43775254 | ||
| Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin | Q43830741 | ||
| Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort ( Hypericum perforatum ). | Q43859427 | ||
| CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro | Q43874398 | ||
| Pharmacological studies in an herbal drug combination of St. John's Wort (Hypericum perforatum) and passion flower (Passiflora incarnata): in vitro and in vivo evidence of synergy between Hypericum and Passiflora in antidepressant pharmacological mo | Q44052645 | ||
| Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase | Q44206787 | ||
| Sequential metabolism is responsible for diltiazem-induced time-dependent loss of CYP3A. | Q44325097 | ||
| Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients | Q44362349 | ||
| Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme | Q44586531 | ||
| The interaction between St John's wort and an oral contraceptive | Q44685310 | ||
| Effects of St. John's wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers | Q44697441 | ||
| Effect of St. John's wort on the pharmacokinetics of theophylline in healthy volunteers | Q44697443 | ||
| Evaluation of the in vitro inhibitory impact of hypericin on placental glutathione S-transferase pi. | Q44699812 | ||
| St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole | Q44787217 | ||
| St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism | Q44827285 | ||
| CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation | Q44872808 | ||
| Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin | Q44923001 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Hypericum perforatum | Q158289 |
| P304 | page(s) | 1047-1062 | |
| P577 | publication date | 2017-09-08 | |
| P1433 | published in | Expert Opinion on Drug Metabolism & Toxicology | Q5421205 |
| P1476 | title | Clinical risks of St John's Wort (Hypericum perforatum) co-administration | |
| P478 | volume | 13 |
| Q89185944 | A Balanced Risk-Benefit Analysis to Determine Human Risks Associated with Pyrrolizidine Alkaloids (PA)-The Case of Herbal Medicinal Products Containing St. John's Wort Extracts (SJW) |
| Q91795701 | Antiproliferative Activity of Hypericum perforatum, Achillea millefolium, and Aloe vera in Interaction with the Prostatic Activity of CD82 |
| Q92136996 | Antiproliferative Effects of Free and Encapsulated Hypericum Perforatum L. Extract and Its Potential Interaction with Doxorubicin for Esophageal Squamous Cell Carcinoma |
| Q64062092 | Influence Factors of the Pharmacokinetics of Herbal Resourced Compounds in Clinical Practice |
| Q88910126 | MAO-A Inhibitory Potential of Terpene Constituents from Ginger Rhizomes-A Bioactivity Guided Fractionation |
| Q92248831 | Medicinal plants and their isolated phytochemicals for the management of chemotherapy-induced neuropathy: therapeutic targets and clinical perspective |
| Q64231967 | PharmActa: Empowering Patients to Avoid Clinical Significant Drug⁻Herb Interactions |
| Q90174714 | Targeting the pregnane X receptor using microbial metabolite mimicry |
| Q52325476 | The Underrated Risks of Tamoxifen Drug Interactions. |
Search more.